Literature DB >> 10400732

Myxoma virus Serp2 is a weak inhibitor of granzyme B and interleukin-1beta-converting enzyme in vitro and unlike CrmA cannot block apoptosis in cowpox virus-infected cells.

P C Turner1, M C Sancho, S R Thoennes, A Caputo, R C Bleackley, R W Moyer.   

Abstract

The Serp2 protein encoded by the leporipoxvirus myxoma virus is essential for full virulence (F. Messud-Petit, J. Gelfi, M. Delverdier, M. F. Amardeilh, R. Py, G. Sutter, and S. Bertagnoli, J. Virol. 72:7830-7839, 1998) and, like crmA of cowpox virus (CPV), is reported to inhibit the interleukin-1beta-converting enzyme (ICE, caspase-1) (F. Petit, S. Bertagnoli, J. Gelfi, F. Fassy, C. Boucraut-Baralon, and A. Milon, J. Virol. 70:5860-5866, 1996). Serp2 and CrmA both contain Asp at the P1 position within the serpin reactive site loop and yet are only 35% identical overall. Serp2 protein was cleaved by ICE but, unlike CrmA, did not form a stable complex with ICE that was detectable by native gel electrophoresis. Attempts to covalently cross-link ICE-serpin inhibitory complexes were successful with CrmA, but no complex between ICE and Serp2 was visible after cross-linking. Purified His10-tagged Serp2 protein was a relatively poor inhibitor of ICE, with a Ki of 80 nM compared to 4 pM for CrmA. Serp2 protein resembled CrmA in that a stable complex with the serine proteinase granzyme B was detectable after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. However, Serp2 was less effective at inhibiting granzyme B activity (Ki = 420 nM) than CrmA (Ki = 100 nM). Finally, Serp2 was tested for the ability to replace CrmA and inhibit apoptosis in LLC-PK1 cells infected with a CPV recombinant deleted for CrmA but expressing Serp2. Unlike wild-type-CPV-infected cells, apoptosis was readily observed in cells infected with the recombinant virus, as indicated by the induction of both nuclear fragmentation and caspase-mediated cleavage of DEVD-AMC [acetyl-Asp-Glu-Val-Asp-(amino-4-methyl coumarin)]. These results indicate that Serp2 is unable to functionally substitute for CrmA within the context of CPV and that the inhibition spectra for Serp2 and CrmA are distinct.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10400732      PMCID: PMC112719     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

Review 1.  Virus proteins that bind cytokines, chemokines or interferons.

Authors:  G L Smith
Journal:  Curr Opin Immunol       Date:  1996-08       Impact factor: 7.486

2.  Human ICE/CED-3 protease nomenclature.

Authors:  E S Alnemri; D J Livingston; D W Nicholson; G Salvesen; N A Thornberry; W W Wong; J Yuan
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

3.  CrmA/SPI-2 inhibition of an endogenous ICE-related protease responsible for lamin A cleavage and apoptotic nuclear fragmentation.

Authors:  A Takahashi; P Y Musy; L M Martins; G G Poirier; R W Moyer; W C Earnshaw
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

4.  The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines.

Authors:  A S Lalani; K Graham; K Mossman; K Rajarathnam; I Clark-Lewis; D Kelvin; G McFadden
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  The T1/35kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues.

Authors:  K A Graham; A S Lalani; J L Macen; T L Ness; M Barry; L Y Liu; A Lucas; I Clark-Lewis; R W Moyer; G McFadden
Journal:  Virology       Date:  1997-03-03       Impact factor: 3.616

6.  Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases.

Authors:  S M Srinivasula; M Ahmad; T Fernandes-Alnemri; G Litwack; E S Alnemri
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

7.  Target protease specificity of the viral serpin CrmA. Analysis of five caspases.

Authors:  Q Zhou; S Snipas; K Orth; M Muzio; V M Dixit; G S Salvesen
Journal:  J Biol Chem       Date:  1997-03-21       Impact factor: 5.157

8.  Characterization of a myxoma virus-encoded serpin-like protein with activity against interleukin-1 beta-converting enzyme.

Authors:  F Petit; S Bertagnoli; J Gelfi; F Fassy; C Boucraut-Baralon; A Milon
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

9.  A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes.

Authors:  J Sun; C H Bird; V Sutton; L McDonald; P B Coughlin; T A De Jong; J A Trapani; P I Bird
Journal:  J Biol Chem       Date:  1996-11-01       Impact factor: 5.157

10.  Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty.

Authors:  A Lucas; L Liu; J Macen; P Nash; E Dai; M Stewart; K Graham; W Etches; L Boshkov; P N Nation; D Humen; M L Hobman; G McFadden
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690

View more
  19 in total

Review 1.  Poxvirus immunomodulatory strategies: current perspectives.

Authors:  J B Johnston; Grant McFadden
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 2.  Evasion and interference: intracellular pathogens modulate caspase-dependent inflammatory responses.

Authors:  Mary K Stewart; Brad T Cookson
Journal:  Nat Rev Microbiol       Date:  2016-05-13       Impact factor: 60.633

Review 3.  Viral serpin therapeutics from concept to clinic.

Authors:  Hao Chen; Donghang Zheng; Jennifer Davids; Mee Yong Bartee; Erbin Dai; Liying Liu; Lyubomir Petrov; Colin Macaulay; Robert Thoburn; Eric Sobel; Richard Moyer; Grant McFadden; Alexandra Lucas
Journal:  Methods Enzymol       Date:  2011       Impact factor: 1.600

Review 4.  The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics.

Authors:  Jia Liu; Sonia Wennier; Grant McFadden
Journal:  Microbes Infect       Date:  2010-09-09       Impact factor: 2.700

Review 5.  The current status and future directions of myxoma virus, a master in immune evasion.

Authors:  Bart Spiesschaert; Grant McFadden; Katleen Hermans; Hans Nauwynck; Gerlinde R Van de Walle
Journal:  Vet Res       Date:  2011-06-09       Impact factor: 3.683

6.  Genome sequence of SG33 strain and recombination between wild-type and vaccine myxoma viruses.

Authors:  Christelle Camus-Bouclainville; Magalie Gretillat; Robert Py; Jacqueline Gelfi; Jean Luc Guérin; Stéphane Bertagnoli
Journal:  Emerg Infect Dis       Date:  2011-04       Impact factor: 6.883

Review 7.  Poxviruses Utilize Multiple Strategies to Inhibit Apoptosis.

Authors:  Daniel Brian Nichols; William De Martini; Jessica Cottrell
Journal:  Viruses       Date:  2017-08-08       Impact factor: 5.048

8.  Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro.

Authors:  Kasinath Viswanathan; Ilze Bot; Liying Liu; Erbin Dai; Peter C Turner; Babajide Togonu-Bickersteth; Jakob Richardson; Jennifer A Davids; Jennifer M Williams; Mee Y Bartee; Hao Chen; Theo J C van Berkel; Erik A L Biessen; Richard W Moyer; Alexandra R Lucas
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

Review 9.  Lessons in détente or know thy host: the immunomodulatory gene products of myxoma virus.

Authors:  Martha C Zúñiga
Journal:  J Biosci       Date:  2003-04       Impact factor: 2.795

10.  Serpin functions in host-pathogen interactions.

Authors:  Jialing Bao; Guoqing Pan; Mortimer Poncz; Junhong Wei; Maoshuang Ran; Zeyang Zhou
Journal:  PeerJ       Date:  2018-04-05       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.